Litcius/Paper detail

LBA80 Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Final analysis results of the RATIONALE-305 study

R-H. Xu, D-Y. Oh, Ken Kato, Tobias Arkenau, Josep Tabernero, Marcia Cruz‐Correa, A. Zimina, Yuxian Bai, Jingwen Shi, Kyung-Woo Lee, Hidekazu Hirano, David R. Spigel, Lucjan Wyrwicz, Roberto Pazo-Cid, L. Li, Yaling Xu, M. Brent McHenry, Shu‐Hua Yang, Markus Moehler

2023Annals of Oncology16 citationsDOI

Topics & Concepts

MedicineCapecitabineInternal medicineInterim analysisPopulationClinical endpointOxaliplatinAdverse effectIntention-to-treat analysisChemotherapy regimenGastroenterologyPlaceboProgression-free survivalPhases of clinical researchChemotherapyOncologyRandomized controlled trialCancerColorectal cancerPathologyEnvironmental healthAlternative medicineGastric Cancer Management and OutcomesGastrointestinal Tumor Research and TreatmentColorectal Cancer Treatments and Studies
LBA80 Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Final analysis results of the RATIONALE-305 study | Litcius